A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population and Treatment
2.2. Statistical Analyses
3. Results
3.1. Efficacy
3.2. Safety
3.3. Cardiac Safety
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Untch, M.; Fasching, P.A.; Konecny, G.E.; Hasmüller, S.; Lebeau, A.; Kreienberg, R.; Camara, O.; Müller, V.; du Bois, A.; Kühn, T.; et al. Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups. J. Clin. Oncol. 2011, 29, 3351–3357. [Google Scholar] [CrossRef] [PubMed]
- Cortazar, P.; Zhang, L.; Untch, M.; Mehta, K.; Costantino, J.P.; Wolmark, N.; Bonnefoi, H.; Cameron, D.; Gianni, L.; Valagussa, P.; et al. Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. Lancet 2014, 384, 164–172. [Google Scholar] [CrossRef] [PubMed]
- Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J. Clin. Oncol. 2002, 20, 1215–1221. [Google Scholar] [CrossRef] [PubMed]
- Moja, L.; Tagliabue, L.; Balduzzi, S.; Parmelli, E.; Pistotti, V.; Guarneri, V.; D’Amico, R. Trastuzumab Containing Regimens for Early Breast Cancer. Cochrane Database Syst. Rev. 2012, 1–65. [Google Scholar] [CrossRef]
- Bowles, E.J.A.; Wellman, R.; Feigelson, H.S.; Onitilo, A.A.; Freedman, A.N.; Delate, T.; Allen, L.A.; Nekhlyudov, L.; Goddard, K.A.B.; Davis, R.L.; et al. Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study. JNCI J. Natl. Cancer Inst. 2012, 104, 1293–1305. [Google Scholar] [CrossRef]
- Perez, E.A.; Rodeheffer, R. Clinical Cardiac Tolerability of Trastuzumab. J. Clin. Oncol. 2004, 22, 322–329. [Google Scholar] [CrossRef]
- Ewer, M.S.; Lippman, S.M. Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity. J. Clin. Oncol. 2005, 23, 2900–2902. [Google Scholar] [CrossRef]
- Zhu, J.; Min, N.; Chen, Y.; Li, X. Neoadjuvant Therapy with vs. without Anthracyclines for HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. Ann. Transl. Med. 2023, 11, 200. [Google Scholar] [CrossRef]
- Schneeweiss, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Hegg, R.; Tausch, C.; Seo, J.H.; Tsai, Y.-F.; Ratnayake, J.; et al. Pertuzumab plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA). Ann. Oncol. 2013, 24, 2278–2284. [Google Scholar] [CrossRef]
- Schneeweiss, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Waldron-Lynch, M.; Eng-Wong, J.; Kirk, S.; Cortés, J. Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer. Eur. J. Cancer 2018, 89, 27–35. [Google Scholar] [CrossRef]
- Van Ramshorst, M.S.; Van Der Voort, A.; Van Werkhoven, E.D.; Mandjes, I.A.; Kemper, I.; Dezentjé, V.O.; Oving, I.M.; Honkoop, A.H.; Tick, L.W.; Van De Wouw, A.J.; et al. Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2018, 19, 1630–1640. [Google Scholar] [CrossRef] [PubMed]
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 4.2024—3 July 2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed on 7 January 2025).
- Hurvitz, S.A.; McAndrew, N.P.; Bardia, A.; Press, M.F.; Pegram, M.; Crown, J.P.; Fasching, P.A.; Ejlertsen, B.; Yang, E.H.; Glaspy, J.A.; et al. A Careful Reassessment of Anthracycline Use in Curable Breast Cancer. npj Breast Cancer 2021, 7, 134. [Google Scholar] [CrossRef] [PubMed]
- Singer, C.F.; Tan, Y.Y.; Fitzal, F.; Steger, G.G.; Egle, D.; Reiner, A.; Rudas, M.; Moinfar, F.; Gruber, C.; Petru, E.; et al. Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clin. Cancer Res. 2017, 23, 3676–3683. [Google Scholar] [CrossRef]
- Kogawa, T.; Fouad, T.M.; Liu, D.D.; Wu, J.; Shen, Y.; Masuda, H.; Fujii, T.; Chavez-MacGregor, M.; Alvarez, R.H.; Hortobágyi, G.N.; et al. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. Oncologist 2016, 21, 21–27. [Google Scholar] [CrossRef]
- Chen, H.; Chen, Q.; Deng, Y. Pathologic Complete Response to Neoadjuvant Anti-HER2 Therapy Is Associated with HER2 Immunohistochemistry Score in HER2-Positive Early Breast Cancer. Medicine 2021, 100, e27632. [Google Scholar] [CrossRef]
- Dowling, G.P.; Keelan, S.; Toomey, S.; Daly, G.R.; Hennessy, B.T.; Hill, A.D.K. Review of the Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer. Front. Oncol. 2023, 13, 1066007. [Google Scholar] [CrossRef]
- Swain, S.M.; Ewer, M.S.; Viale, G.; Delaloge, S.; Ferrero, J.-M.; Verrill, M.; Colomer, R.; Vieira, C.; Werner, T.L.; Douthwaite, H.; et al. Pertuzumab, Trastuzumab, and Standard Anthracycline- and Taxane-Based Chemotherapy for the Neoadjuvant Treatment of Patients with HER2-Positive Localized Breast Cancer (BERENICE): A Phase II, Open-Label, Multicenter, Multinational Cardiac Safety Study. Ann. Oncol. 2018, 29, 646–653. [Google Scholar] [CrossRef]
- Dang, C.; Ewer, M.S.; Delaloge, S.; Ferrero, J.-M.; Colomer, R.; De La Cruz-Merino, L.; Werner, T.L.; Dadswell, K.; Verrill, M.; Eiger, D.; et al. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers 2022, 14, 2596. [Google Scholar] [CrossRef]
- Van Der Voort, A.; Van Ramshorst, M.S.; Van Werkhoven, E.D.; Mandjes, I.A.; Kemper, I.; Vulink, A.J.; Oving, I.M.; Honkoop, A.H.; Tick, L.W.; Van De Wouw, A.J.; et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021, 7, 978. [Google Scholar] [CrossRef]
- Pérez-García, J.M.; Gebhart, G.; Ruiz Borrego, M.; Stradella, A.; Bermejo, B.; Schmid, P.; Marmé, F.; Escrivá-de-Romani, S.; Calvo, L.; Ribelles, N.; et al. Chemotherapy De-Escalation Using an 18F-FDG-PET-Based Pathological Response-Adapted Strategy in Patients with HER2-Positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-Label, Non-Comparative, Phase 2 Trial. Lancet Oncol. 2021, 22, 858–871. [Google Scholar] [CrossRef]
- Pérez-García, J.M.; Cortés, J.; Ruiz-Borrego, M.; Colleoni, M.; Stradella, A.; Bermejo, B.; Dalenc, F.; Escrivá-de-Romaní, S.; Calvo Martínez, L.; Ribelles, N.; et al. 3-Year Invasive Disease-Free Survival with Chemotherapy de-Escalation Using an 18F-FDG-PET-Based, Pathological Complete Response-Adapted Strategy in HER2-Positive Early Breast Cancer (PHERGain): A Randomised, Open-Label, Phase 2 Trial. Lancet 2024, 403, 1649–1659. [Google Scholar] [CrossRef] [PubMed]
- Loibl, S.; Jackisch, C.; Schneeweiss, A.; Schmatloch, S.; Aktas, B.; Denkert, C.; Wiebringhaus, H.; Kümmel, S.; Warm, M.; Paepke, S.; et al. Dual HER2-Blockade with Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer: A Subanalysis of Data from the Randomized Phase III GeparSepto Trial. Ann. Oncol. 2017, 28, 497–504. [Google Scholar] [CrossRef] [PubMed]
- Untch, M.; Jackisch, C.; Schneeweiss, A.; Schmatloch, S.; Aktas, B.; Denkert, C.; Schem, C.; Wiebringhaus, H.; Kümmel, S.; Warm, M.; et al. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69–GeparSepto. J. Clin. Oncol. 2019, 37, 2226–2234. [Google Scholar] [CrossRef]
- Masuda, N.; Ohtani, S.; Takano, T.; Inoue, K.; Suzuki, E.; Nakamura, R.; Bando, H.; Ito, Y.; Ishida, K.; Yamanaka, T.; et al. A Randomized, 3-Arm, Neoadjuvant, Phase 2 Study Comparing Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCbHP), TCbHP Followed by Trastuzumab Emtansine and Pertuzumab (T-DM1+P), and T-DM1+P in HER2-Positive Primary Breast Cancer. Breast Cancer Res. Treat. 2020, 180, 135–146. [Google Scholar] [CrossRef]
- Takano, T.; Masuda, N.; Ito, M.; Inoue, K.; Tanabe, Y.; Kawaguchi, K.; Yasojima, H.; Bando, H.; Nakamura, R.; Yamanaka, T.; et al. Long-Term Outcomes of Neoadjuvant Trastuzumab Emtansine + Pertuzumab (T-DM1 + P) and Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCbHP) for HER2-Positive Primary Breast Cancer: Results of the Randomized Phase 2 JBCRG20 Study (Neo-Peaks). Breast Cancer Res. Treat. 2024, 207, 33–48. [Google Scholar] [CrossRef]
- Hurvitz, S.A.; Martin, M.; Jung, K.H.; Huang, C.-S.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.-F.; et al. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes from the Phase III KRISTINE Study. J. Clin. Oncol. 2019, 37, 2206–2216. [Google Scholar] [CrossRef]
- Loibl, S.; Mano, M.; Untch, M.; Huang, C.-S.; Mamounas, E.; Wolmark, N.; Knott, A.; Siddiqui, A.; Boulet, T.; Nyawira, B.; et al. Abstract GS03-12: Phase III Study of Adjuvant Ado-Trastuzumab Emtansine vs. Trastuzumab for Residual Invasive HER2-Positive Early Breast Cancer after Neoadjuvant Chemotherapy and HER2-Targeted Therapy: KATHERINE Final IDFS and Updated OS Analysis. Cancer Res. 2024, 84, GS03-12. [Google Scholar] [CrossRef]
- Geyer, C.E.; Blum, J.L.; Yothers, G.; Asmar, L.; Flynn, P.J.; Robert, N.J.; Hopkins, J.O.; O’Shaughnessy, J.A.; Rastogi, P.; Puhalla, S.L.; et al. Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 [NRG Oncology]). J. Clin. Oncol. 2024, 42, 1344–1349. [Google Scholar] [CrossRef]
ACTHP No. (%) | DCbHP No. (%) | p-Value | |
---|---|---|---|
Total | 106 (59.2) | 73 (40.8) | |
Mean age | 48.4 | 48.4 | 0.98 |
T stage | 0.43 | ||
T = 1/2 | 75 (70.8) | 56 (76.7) | |
T = 3/4 | 30 (28.6) | 17 (23.3) | |
HER2 IHC status | 0.125 | ||
HER2 +3 | 80 (75.5) | 62 (84.9) | |
HER2 + 2 (FISH pos) | 26 (24.5) | 11 (15.1) | |
HR status | 0.65 | ||
ER neg | 40 (37.7) | 30 (41.1) | |
ER pos | 66 (62.3) | 43 (58.9) | |
Nodal status | 0.846 | ||
N pos | 74 (69.8) | 51 (69.9) | |
N neg | 32 (30.2) | 22 (30.1) |
Total Number of Patients per Subgroup, No. | pCR Rates in Every Subgroup No. (%) | |
---|---|---|
Total | 179 | 113 (63.1) |
HER-2 + 3 | 142 | 103 (72.5) |
HER-2 + 2 FISH pos | 37 | 10 (27) |
ER neg | 70 | 60 (85.7) |
ER pos | 109 | 53 (48.6) |
N pos | 125 | 72 (57.6) |
N neg | 51 | 38 (74.5) |
Therapy Protocol | p-Value [2-Sided] | OR [Odds Ratio] | 95% CI Confidence Interval | ||||
---|---|---|---|---|---|---|---|
ACTHP | DCbHP | ||||||
No. | No. with pCR (%) | No. | No. with pCR (%) | ||||
Total | 106 | 71 (67) | 73 | 42 (57.5) | 0.129 | 1.50 | 0.8–2.77 |
HER2 + 3 | 80 | 64 (80) | 62 | 39 (62.9) | 0.036 | 2.36 | 1.11–5.00 |
HER2 + 2 FISH pos | 26 | 7 (26.9) | 11 | 3 (27.3) | 1.0 | 0.98 | 0.201–4.79 |
ER neg | 40 | 37 (92.5) | 30 | 23 (76.7) | 0.09 | 3.75 | 0.88–15.99 |
ER pos | 66 | 34 (51.5) | 43 | 19 (44.2) | 0.56 | 1.34 | 0.62–2.90 |
N pos | 74 | 46 (62.2) | 51 | 26 (50.9) | 0.27 | 1.58 | 0.77–3.25 |
N neg | 31 | 24 (77.4) | 20 | 14 (70) | 0.74 | 1.47 | 0.41–5.25 |
T1–2 | 75 | 50 (66.7) | 56 | 29 (51.8) | 0.09 | 1.86 | 0.92–3.79 |
T3–4 | 30 | 20 (66.7) | 17 | 13 (76.5) | 0.48 | 0.62 | 0.16–2.38 |
ACTHP No (%) | DCbHP No (%) | p-Value | OR [95% CI] | |
---|---|---|---|---|
LVEF reduction | 7 (6.6) | 0 (0) | 0.043 | 11.08 * [0.6229–197.1] |
Hospitalization | 15 (14.2) | 10 (13.7) | 0.835 | 1.197 [0.522–2.74] |
Febrile neutropenia | 7 (6.6) | 1 (1.4) | 0.1441 | 5.091 [0.8532–58.07] |
Regimen | No of pts. | Total Treatment Cycles | pCR pT0/is ypN0 Unless Otherwise Stated | DFS/EFS (%) | OS (%) [95% CI] | |
---|---|---|---|---|---|---|
Tryphaena [9,10] | FECHP → THP FEC → THP DCbHP | 73 75 77 | 6 6 6 | 50.7% 45.3% 51.9% ypT0/ypN0 | 87 88 87 DFS (3 y) | 94 94 93 (3 y) |
Berenice [18,19] | AC → THP FEC → THP | 199 201 | 8 8 | 62% 61% | EFS (5 y) 91 EFS (5 y) 89 | 96.1 (93.3–98.9) 93.8 (90.3–97.2) (5 y) |
TRAIN-2 [11,20] | FEC → TCbHP TCbHP (X9) | 211 206 | 9 9 | 67% 68% | EFS (3 y) 93 EFS (3 y) 94 | 98 (95.7–99.7) 98 (96.4–100) (3 y) |
PHERgain [21,22] | TCbHP | 71 | 6 | 58% | DFS (3 y) 98 | N/A |
Gepar-Septo [23,24] (For the 396 HER2-pos patients in the trial | TaxaneHP → ECHP | 396 | 8 | 66% | N/A | N/A |
Neopeaks [25,26] | DCbHP arm | 51 | 6 | 57% | 80.7 DFS (5 y) | 97.5 (94.1–98.9) (5 y) |
KRISTINE [27] | DCbPH | 221 | 6 | 55.7% | iDFS (3 y) 94 | N/A |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Itay, A.; Globus, O.; Levanon, K.; Sella, T.; Bernstein-Molho, R.; Shapira, T.; Oedegaard, C.; Fourey, D.; Nili Gal Yam, E. A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients. Cancers 2025, 17, 250. https://doi.org/10.3390/cancers17020250
Itay A, Globus O, Levanon K, Sella T, Bernstein-Molho R, Shapira T, Oedegaard C, Fourey D, Nili Gal Yam E. A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients. Cancers. 2025; 17(2):250. https://doi.org/10.3390/cancers17020250
Chicago/Turabian StyleItay, Amit, Opher Globus, Keren Levanon, Tal Sella, Rinat Bernstein-Molho, Tal Shapira, Cecilie Oedegaard, Dana Fourey, and Einav Nili Gal Yam. 2025. "A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients" Cancers 17, no. 2: 250. https://doi.org/10.3390/cancers17020250
APA StyleItay, A., Globus, O., Levanon, K., Sella, T., Bernstein-Molho, R., Shapira, T., Oedegaard, C., Fourey, D., & Nili Gal Yam, E. (2025). A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients. Cancers, 17(2), 250. https://doi.org/10.3390/cancers17020250